Tekturna works better in older patients: Novartis

ZURICH (Reuters) - Novartis AG’s Tekturna reduced blood pressure in patients aged 65 and over by significantly more than the older drug ramipril, the Swiss drugmaker said on Tuesday.

Data showed that Tekturna — known as Rasilez in Europe — gave an additional reduction in systolic blood pressure of 2.3 millimeters of mercury (mmHG) compared with ramipril after 12 weeks of treatment, Novartis said in a statement.

Ramipril, a so-called ACE inhibitor which is marketed in the United States as Altace by King Pharmaceuticals Inc, acts on a compound called angiotensin to regulate blood pressure.

The data, from a trial called AGELESS, was presented at an American Heart Association meeting.

(Reporting by Sam Cage; Editing by Greg Mahlich)

Source

--------------------------------------------------------------------------------------------
Related Posts:


By Susan Heavey WASHINGTON (Reuters) - Data show Novartis AG’s combination malaria drug Coartem appears to work and causes few serious side effects, U.S. Food and Drug Administration regulatory staff said in documents released on Monday. “The majority of AEs (adverse events) were of mild or moderate intensity. Deaths … and SAEs (serious adverse events) … were

Full Post: Novartis malaria drug safe, effective: FDA
--------------------------------------------------------------------------------------------

ZURICH (Reuters) - Novartis AG’s cancer drug Tasigna was effective and helped achieve rapid responses as an initial therapy in newly diagnosed patients with a life threatening form of leukemia, the company said. Data from two mid-stage clinical trials presented at an American Society of Hematology meeting showed there was rapid elimination of cancer cells in

Full Post: Novartis leukemia drugs show promise
--------------------------------------------------------------------------------------------

By Michael Kahn LONDON (Reuters) - An international research team has identified a tiny piece of genetic material that plays a key role in heart failure, and shown how an experimental compound prevents the condition in mice, scientists reported on Sunday. The researchers used a treatment from Regulus Therapeutics — a joint venture between U.S. biotech companies

Full Post: Gene “silencing” drug blocks heart disease in mice
--------------------------------------------------------------------------------------------

LOS ANGELES (Reuters) - A combination of Genentech Inc’s cancer drug Rituxan and chemotherapy reduces by 41 percent the risk of death or cancer progression, compared with chemotherapy alone, for patients with a common form of leukemia, the company said on Saturday. Results from the pivotal- or final-stage trial found that previously untreated patients given the

Full Post: Genentech drug boosts leukemia patient survival
--------------------------------------------------------------------------------------------

By Will Dunham WASHINGTON (Reuters) - The number of Americans with high blood pressure is on the rise thanks in large part to growing rates of obesity, researchers said on Tuesday. But increasing numbers of those with high blood pressure, also called hypertension, are getting the condition treated, researchers from the U.S. government’s National Institutes of Health

Full Post: More Americans getting high blood pressure: study

Site Navigation

Most Read

Search